 <h1>Orlistat Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of orlistat include:</b> bowel urgency, frequent bowel movements, oily evacuation, oily rectal leakage, steatorrhea, and flatulence with discharge. <b>Other side effects include:</b> fecal incontinence.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to orlistat: oral capsule</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, orlistat may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking orlistat:</p><p>
<i>More common</i>
</p><ul>
<li>Bladder pain</li>
<li>body aches</li>
<li>chills</li>
<li>cough</li>
<li>diarrhea</li>
<li>difficulty with breathing</li>
<li>ear congestion</li>
<li>fever</li>
<li>general feeling of discomfort or illness</li>
<li>headache</li>
<li>loss of appetite</li>
<li>loss of voice</li>
<li>lower back or side pain</li>
<li>muscle aches and pains</li>
<li>nasal congestion</li>
<li>nausea</li>
<li>runny nose</li>
<li>shivering</li>
<li>sneezing</li>
<li>sore throat</li>
<li>sweating</li>
<li>trouble sleeping</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Tightness in the chest</li>
<li>tooth or gum problems</li>
<li>troubled breathing</li>
<li>wheezing</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Bloody or cloudy urine</li>
<li>change in hearing</li>
<li>contagious diarrhea</li>
<li>dark urine</li>
<li>difficult or painful urination</li>
<li>earache</li>
<li>fast heartbeat</li>
<li>frequent urge to urinate</li>
<li>general tiredness and weakness</li>
<li>hives</li>
<li>hoarseness</li>
<li>irritation</li>
<li>itching</li>
<li>joint pain, stiffness, or swelling</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>light-colored stools</li>
<li>noisy breathing</li>
<li>pain in the ears</li>
<li>rash</li>
<li>redness of the skin</li>
<li>shortness of breath</li>
<li>skin blisters</li>
<li>swelling of the eyelids, face, lips, hands, or feet</li>
<li>troubled swallowing</li>
<li>upper right abdominal or stomach pain</li>
<li>yellow eyes and skin</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Anxiety</li>
<li>bloating</li>
<li>blurred vision</li>
<li>cold sweats</li>
<li>coma</li>
<li>confusion</li>
<li>constipation</li>
<li>cool, pale skin</li>
<li>depression</li>
<li>dizziness</li>
<li>dry skin and hair</li>
<li>feeling cold</li>
<li>hair loss</li>
<li>hoarseness or husky voice</li>
<li>increased hunger</li>
<li>indigestion</li>
<li>loss of appetite</li>
<li>muscle cramps and stiffness</li>
<li>nervousness</li>
<li>nightmares</li>
<li>pains in the stomach, side, or abdomen, possibly radiating to the back</li>
<li>seizures</li>
<li>weight gain</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of orlistat may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Abdominal or stomach pain or discomfort</li>
<li>back pain</li>
<li>difficulty with moving</li>
<li>gas with leaky bowel movements</li>
<li>inability to hold bowel movement</li>
<li>increases in bowel movements </li>
<li>loss of bowel control</li>
<li>oily bowel movements</li>
<li>oily spotting of underclothes</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Itching of the vagina or genital area</li>
<li>menstrual changes</li>
<li>pain during sexual intercourse</li>
<li>rectal pain or discomfort</li>
<li>thick, white vaginal discharge with no odor or with a mild odor</li>
</ul><p>
<!-- end oral capsule --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to orlistat: oral capsule</i></p><h3>General</h3><p>The most commonly reported adverse events have included oily spotting, flatus with discharge, fecal urgency fatty/oily stool, oily evacuation, increased defecation and fecal incontinence.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Gastrointestinal events usually occur within the first 3 months.  Approximately 50% of all GI events lasted for less than 1 week with a majority lasting no more than 4 weeks.  Although, in some individuals, gastrointestinal events have lasted 6 months or more.  In clinical trials, gastrointestinal adverse effects were the most common reason for treatment discontinuation.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Oily spotting (up to 26.6%), flatus with discharge (up to 23.9%), fecal urgency (up to 22.1%), fatty/oily stool (up to 20%), oily evacuation (up to 11.9%), increased defecation (up to 10.8%), abdominal pain/discomfort (up to 25.5%)</p>
<p><b>Common</b> (1% to 10%): Fecal incontinence, nausea, infectious diarrhea, rectal pain/discomfort, tooth disorder, gingival disorder, vomiting </p>
<p><b>Frequency not reported</b>: Abdominal distention </p>
<p><b>Postmarketing reports</b>: Pancreatitis, lower gastrointestinal bleeding<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Postmarketing reports</b>: Increases in hepatic transaminases, alkaline phosphatase elevations, hepatitis, hepatic failure, liver transplant<sup>[Ref]</sup></p><p>Reports of hepatic failure have been received during postmarketing surveillance, with some of these cases resulting in liver transplant or death.  Rare cases of increased transaminases, alkaline phosphatase, and hepatitis have been received.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Postmarketing reports</b>: Hypersensitivity reactions including pruritus, rash, urticaria, angioedema, bronchospasm, and anaphylaxis; at least one case of cutaneous leukocytoclastic vasculitis<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Hypoglycemia, at least one case of diabetic ketoacidosis; polyuria, polydipsia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Cases of leukocytoclastic vasculitis have been reported during the postmarketing period.  Clinical signs include palpable purpura, maculopapular lesions, or bullous eruption.<sup>[Ref]</sup></p><p><b>Postmarketing reports</b>: Bullous eruption, leukocytoclastic vasculitis<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Postmarketing reports</b>: Acute oxalate nephropathy<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Convulsions have been reported in patients concomitantly receiving this drug with antiepileptic drugs.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Headache (up to 30.6%) </p>
<p><b>Common</b> (1% to 10%): Dizziness </p>
<p><b>Postmarketing reports</b>: Convulsions<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Sleep disorder, anxiety, depression<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Influenza (up to 39.7%), upper respiratory infection (up to 38.1%) </p>
<p><b>Common</b> (1% to 10%): Lower respiratory infection, ear, nose &amp; throat symptoms<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Back pain (up to 13.9%) </p>
<p><b>Common</b> (1% to 10%): Arthritis, myalgia, joint disorder, tendonitis<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Menstrual irregularity, vaginitis, urinary tract infection<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Pedal edema<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Postmarketing reports</b>: Decreased prothrombin, increased INR and unbalanced anticoagulant treatment<sup>[Ref]</sup></p><p>Decreased prothrombin and increased INR resulting in unbalanced anticoagulant treatment has been reported in patients treated concomitantly with anticoagulants.<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fatigue, otitis<sup>[Ref]</sup></p><h3>Endocrine</h3><p>For patients receiving levothyroxine, hypothyroidism has been reported requiring an adjustment to levothyroxine therapy.<sup>[Ref]</sup></p><p><b>Postmarketing reports</b>: Hypothyroidism<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Xenical (orlistat)." Roche Laboratories, Nutley, NJ. </p><p id="ref_2">2. "Product Information. alli (orlistat)." GlaxoSmithKline Healthcare, Pittsburgh, PA. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about orlistat</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>337 Reviews</li>
<li>Drug class: peripherally acting antiobesity agents</li>
<li>FDA Alerts (2)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Orlistat &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Xenical, Alli</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Nonalcoholic Fatty Liver Disease</li>
<li>Obesity</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to orlistat: oral capsule</i></p><h3>General</h3><p>The most commonly reported adverse events have included oily spotting, flatus with discharge, fecal urgency fatty/oily stool, oily evacuation, increased defecation and fecal incontinence.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Gastrointestinal events usually occur within the first 3 months.  Approximately 50% of all GI events lasted for less than 1 week with a majority lasting no more than 4 weeks.  Although, in some individuals, gastrointestinal events have lasted 6 months or more.  In clinical trials, gastrointestinal adverse effects were the most common reason for treatment discontinuation.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Oily spotting (up to 26.6%), flatus with discharge (up to 23.9%), fecal urgency (up to 22.1%), fatty/oily stool (up to 20%), oily evacuation (up to 11.9%), increased defecation (up to 10.8%), abdominal pain/discomfort (up to 25.5%)</p><p><b>Common</b> (1% to 10%): Fecal incontinence, nausea, infectious diarrhea, rectal pain/discomfort, tooth disorder, gingival disorder, vomiting </p><p><b>Frequency not reported</b>: Abdominal distention </p><p><b>Postmarketing reports</b>: Pancreatitis, lower gastrointestinal bleeding<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Postmarketing reports</b>: Increases in hepatic transaminases, alkaline phosphatase elevations, hepatitis, hepatic failure, liver transplant<sup>[Ref]</sup></p><p>Reports of hepatic failure have been received during postmarketing surveillance, with some of these cases resulting in liver transplant or death.  Rare cases of increased transaminases, alkaline phosphatase, and hepatitis have been received.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Postmarketing reports</b>: Hypersensitivity reactions including pruritus, rash, urticaria, angioedema, bronchospasm, and anaphylaxis; at least one case of cutaneous leukocytoclastic vasculitis<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Hypoglycemia, at least one case of diabetic ketoacidosis; polyuria, polydipsia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Cases of leukocytoclastic vasculitis have been reported during the postmarketing period.  Clinical signs include palpable purpura, maculopapular lesions, or bullous eruption.<sup>[Ref]</sup></p><p><b>Postmarketing reports</b>: Bullous eruption, leukocytoclastic vasculitis<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Postmarketing reports</b>: Acute oxalate nephropathy<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Convulsions have been reported in patients concomitantly receiving this drug with antiepileptic drugs.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Headache (up to 30.6%) </p><p><b>Common</b> (1% to 10%): Dizziness </p><p><b>Postmarketing reports</b>: Convulsions<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Sleep disorder, anxiety, depression<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Influenza (up to 39.7%), upper respiratory infection (up to 38.1%) </p><p><b>Common</b> (1% to 10%): Lower respiratory infection, ear, nose &amp; throat symptoms<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Back pain (up to 13.9%) </p><p><b>Common</b> (1% to 10%): Arthritis, myalgia, joint disorder, tendonitis<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Menstrual irregularity, vaginitis, urinary tract infection<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Pedal edema<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Postmarketing reports</b>: Decreased prothrombin, increased INR and unbalanced anticoagulant treatment<sup>[Ref]</sup></p><p>Decreased prothrombin and increased INR resulting in unbalanced anticoagulant treatment has been reported in patients treated concomitantly with anticoagulants.<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fatigue, otitis<sup>[Ref]</sup></p><h3>Endocrine</h3><p>For patients receiving levothyroxine, hypothyroidism has been reported requiring an adjustment to levothyroxine therapy.<sup>[Ref]</sup></p><p><b>Postmarketing reports</b>: Hypothyroidism<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Xenical (orlistat)." Roche Laboratories, Nutley, NJ. </p><p id="ref_2">2. "Product Information. alli (orlistat)." GlaxoSmithKline Healthcare, Pittsburgh, PA. </p><h2>More about orlistat</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>337 Reviews</li>
<li>Drug class: peripherally acting antiobesity agents</li>
<li>FDA Alerts (2)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Orlistat &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Nonalcoholic Fatty Liver Disease</li>
<li>Obesity</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>